HUP0102272A3 - For stimulating g astrointestinal motility use of growth hormone secretagogue - Google Patents

For stimulating g astrointestinal motility use of growth hormone secretagogue

Info

Publication number
HUP0102272A3
HUP0102272A3 HU0102272A HUP0102272A HUP0102272A3 HU P0102272 A3 HUP0102272 A3 HU P0102272A3 HU 0102272 A HU0102272 A HU 0102272A HU P0102272 A HUP0102272 A HU P0102272A HU P0102272 A3 HUP0102272 A3 HU P0102272A3
Authority
HU
Hungary
Prior art keywords
astrointestinal
motility
stimulating
growth hormone
hormone secretagogue
Prior art date
Application number
HU0102272A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU0102272D0 publication Critical patent/HU0102272D0/hu
Publication of HUP0102272A2 publication Critical patent/HUP0102272A2/hu
Publication of HUP0102272A3 publication Critical patent/HUP0102272A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0102272A 2000-05-31 2001-05-30 For stimulating g astrointestinal motility use of growth hormone secretagogue HUP0102272A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20823400P 2000-05-31 2000-05-31

Publications (3)

Publication Number Publication Date
HU0102272D0 HU0102272D0 (en) 2001-08-28
HUP0102272A2 HUP0102272A2 (hu) 2002-02-28
HUP0102272A3 true HUP0102272A3 (en) 2003-09-29

Family

ID=22773794

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102272A HUP0102272A3 (en) 2000-05-31 2001-05-30 For stimulating g astrointestinal motility use of growth hormone secretagogue

Country Status (14)

Country Link
US (2) US6548501B2 (hu)
EP (1) EP1159964B1 (hu)
JP (4) JP3842987B2 (hu)
KR (1) KR20010109139A (hu)
AT (1) ATE446758T1 (hu)
AU (1) AU4811401A (hu)
CA (1) CA2349142C (hu)
DE (1) DE60140285D1 (hu)
ES (1) ES2333097T3 (hu)
HU (1) HUP0102272A3 (hu)
IL (1) IL143388A0 (hu)
MY (1) MY134190A (hu)
NZ (1) NZ512072A (hu)
ZA (1) ZA200104396B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) * 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6821285B2 (en) * 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6494888B1 (en) * 1999-06-22 2002-12-17 Ndo Surgical, Inc. Tissue reconfiguration
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
JP4928261B2 (ja) * 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) * 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1641494A1 (en) * 2003-06-25 2006-04-05 F. Hoffmann-La Roche Ag Tritiated growth hormone secretagogue mk-0677
DE602004030344D1 (de) 2003-07-31 2011-01-13 Tranzyme Pharma Inc Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
IL158658A0 (en) * 2003-10-29 2004-05-12 Moshe Schwarzberg Prokinetic drugs assistance to small intestine imaging
WO2005097261A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
US20070141156A1 (en) * 2005-12-21 2007-06-21 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
RU2007107349A (ru) 2004-07-28 2008-09-10 Глэксо Груп Лимитед (GB) Пиперазиновые производные, применение для лечения желудочно-кишечных расстройств
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
AU2005272598B2 (en) 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
WO2006023608A2 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US8138218B2 (en) * 2005-07-22 2012-03-20 Ipsen Pharma S.A.S. Growth hormone secretagogues
WO2007041278A2 (en) 2005-09-29 2007-04-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Composition and methods for stimulating gastrointestinal motility
US7576606B2 (en) * 2007-07-25 2009-08-18 D2Audio Corporation Digital PWM amplifier having a low delay corrector
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009531385A (ja) 2006-03-31 2009-09-03 グラクソ グループ リミテッド 成長ホルモン分泌促進物質（ｇｈｓ）受容体アゴニストとしてのピペラジン誘導体
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
JP2010518158A (ja) * 2007-02-13 2010-05-27 ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド 成長ホルモン分泌促進物質を用いた細胞増殖性障害の治療方法
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
US20080234703A1 (en) * 2007-03-23 2008-09-25 Ethicon Endo-Surgery, Inc. Tissue approximation system
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US7728658B2 (en) * 2007-07-25 2010-06-01 D2Audio Corporation Low-noise, low-distortion digital PWM amplifier
EP2224929B1 (en) 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
KR20100102157A (ko) * 2007-12-21 2010-09-20 헬신 세라퓨틱스 (유.에스.) 인크. 이파몰레린을 이용하여 위장관계 운동성을 촉진시키는 방법
JP5816087B2 (ja) * 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｓｍｏアンタゴニストとしての飽和二環式複素環誘導体
KR100991032B1 (ko) * 2008-12-08 2010-10-29 삼일제약주식회사 위장관 운동 조절용 약학 조성물
EP2540721B1 (en) * 2010-02-26 2016-12-14 RaQualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
WO2012021874A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with thioether linkers
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
AU2013221432B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3524260B1 (en) 2012-09-27 2023-09-13 Elanco Animal Health Incorporated Pharmaceutical compositions for treatment of inappetence
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
JP6299683B2 (ja) 2015-06-25 2018-03-28 トヨタ自動車株式会社 燃料電池システム
PL3352752T3 (pl) 2015-09-21 2022-04-19 Lumos Pharma Inc. Wykrywanie i leczenie niedoboru hormonu wzrostu

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0400051B1 (en) 1988-01-28 1995-05-10 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
DE68919213T2 (de) 1988-01-28 1995-05-11 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5726319A (en) 1992-11-06 1998-03-10 Merck & Co., Inc. Biphenyl substituted dipeptide analogs promote release of growth hormone
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
AU8083694A (en) 1993-10-19 1995-05-08 Merck & Co., Inc. Combination of bisphosphonates and growth hormone secretagogues
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
SK281963B6 (sk) 1993-12-23 2001-09-11 Novo Nordisk A/S Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie
PL181286B1 (pl) 1993-12-23 2001-07-31 Novo Nordisk As Zwiazki o wlasciwosciach uwalniania hormonu wzrostu i zawierajace je kompozycje farmaceutyczne PL PL PL PL PL PL PL PL
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
US5783582A (en) 1994-07-20 1998-07-21 Merck & Co., Inc. Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1996022996A1 (fr) 1995-01-25 1996-08-01 Nippon Chemiphar Co., Ltd. Derives de dihydrophenazine
ATE272069T1 (de) 1995-01-27 2004-08-15 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
WO1996024587A1 (en) 1995-02-09 1996-08-15 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU4534596A (en) 1995-02-09 1996-08-27 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
EP0823904A4 (en) 1995-04-19 1998-09-09 Merck & Co Inc METHOD FOR PRODUCING SPIROINDOLINES
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (en) 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
WO1997000894A1 (en) 1995-06-22 1997-01-09 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU6724496A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
AU6772996A (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues
WO1997011697A1 (en) 1995-09-26 1997-04-03 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
CA2235511A1 (en) 1995-10-27 1997-05-01 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
CA2240186A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
CA2240427C (en) 1995-12-13 2007-08-14 Merck & Co., Inc. Growth hormone secretagogue receptor family
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
WO1997022367A1 (en) 1995-12-20 1997-06-26 Merck & Co., Inc. Radiolabeled growth hormone secretagogue
HUP9802580A3 (en) 1995-12-22 1999-03-29 Novo Nordisk As Compounds with growth hormone releasing properties
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
AU2722297A (en) 1996-04-03 1997-10-22 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
SE9601397D0 (sv) 1996-04-12 1996-04-12 Pharmacia Ab Use of growth hormone
WO1997040071A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5919777A (en) 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2252761A1 (en) 1996-04-24 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU2931997A (en) 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
WO1997043278A1 (en) 1996-05-14 1997-11-20 Novo Nordisk A/S Somatostatin agonists and antagonists
US6071926A (en) 1996-05-22 2000-06-06 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
JP2000512274A (ja) 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ 骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤
DE69734215T2 (de) 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
WO1998010653A1 (en) 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
WO1998051687A1 (en) 1997-05-14 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Piperidino derivatives which promote growth hormone release
JP4116097B2 (ja) 1997-06-20 2008-07-09 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性をもつ化合物
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
DE69837264T2 (de) 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
CA2301566A1 (en) 1997-08-22 1999-03-04 Kaken Pharmaceutical Co., Ltd. N-acylated lipophilic amino acid derivatives
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6194578B1 (en) * 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
CA2377721A1 (en) * 1999-06-30 2001-01-04 Zymogenetics, Inc. Sgip peptides
AU2001264977B2 (en) * 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
ES2333097T3 (es) * 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.

Also Published As

Publication number Publication date
ATE446758T1 (de) 2009-11-15
US20020042419A1 (en) 2002-04-11
CA2349142A1 (en) 2001-11-30
CA2349142C (en) 2005-07-12
NZ512072A (en) 2002-10-25
AU4811401A (en) 2001-12-06
IL143388A0 (en) 2002-04-21
HU0102272D0 (en) 2001-08-28
US6852722B2 (en) 2005-02-08
JP2006265270A (ja) 2006-10-05
US6548501B2 (en) 2003-04-15
MY134190A (en) 2007-11-30
US20030225096A1 (en) 2003-12-04
JP2013139482A (ja) 2013-07-18
HUP0102272A2 (hu) 2002-02-28
JP3842987B2 (ja) 2006-11-08
DE60140285D1 (de) 2009-12-10
EP1159964B1 (en) 2009-10-28
JP2015127344A (ja) 2015-07-09
ES2333097T3 (es) 2010-02-17
KR20010109139A (ko) 2001-12-08
EP1159964A3 (en) 2003-10-01
EP1159964A2 (en) 2001-12-05
JP2002012556A (ja) 2002-01-15
ZA200104396B (en) 2002-11-29

Similar Documents

Publication Publication Date Title
HUP0102272A3 (en) For stimulating g astrointestinal motility use of growth hormone secretagogue
AU5959201A (en) Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
IL153067A0 (en) Growth hormone secretagogues
PL337654A1 (en) Substituted dipeptide tartrates as growth hormone stimulating agents
NZ513852A (en) Intermittent administration of a growth hormone secretagogue
AU2002342653A8 (en) Modified growth hormone
PL338883A1 (en) Growth hormone secretion stimulating compounds
HUP0103072A3 (en) Use of growth hormone secretagogues
HUP0203243A2 (en) Kits containing growth hormone secretagogue
HU0102698D0 (en) Use of growth hormone secretagogues for treatment of physical performance decline
IL147253A0 (en) Growth hormone formulations
GB0007309D0 (en) Crystalline form V|| of cabergoline
EP1158996A4 (en) NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
IL143941A0 (en) Use of growth hormone secretagogues for stimulating or increasing appetite
HUP0402334A3 (en) Modified human growth hormone
HUP0401589A3 (en) New peptides - analogs of human growth hormone-releasing hormone
PL362980A1 (en) Treatment of sexual dysfunction
IL149200A0 (en) Peptides for treatment of erectile dysfunction
GB0106565D0 (en) Growth hormone treatment
IL143990A0 (en) Bone stimulating factor
IL142480A0 (en) Tissue growth stimulating system
HK1075449A1 (en) Growth hormone secretagogues
EP1230928A4 (en) USE OF PEPTIDE
SI1326851T1 (en) Substituted dipeptides as growth hormone secretagogues
GB9916252D0 (en) Growth hormone formulation

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees